Calgary, AB – TheNewswire - January 4, 2023 – Universal Ibogaine Inc. ( TSXV:IBO ) (“ UI ” or the “ Company ”), a life sciences company with a mission to transform the addiction treatment industry with medicalized ibogaine-centered care, is pleased to provide a year end summary of 2022 accomplishments. Nick Karos, Chief Executive Officer and board member of [...]

Calgary, AB – TheNewswire - December 9, 2022 – Universal Ibogaine Inc. ( TSXV:IBO ) (“ UI ” or the “ Company ”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, announces that it has agreed to issue 350,000 common shares (at a deemed price of $0.05) as part of a settlement agreement related to a claim filed in August 2021 by a [...]

Calgary, AB – December 1, 2022 – Universal Ibogaine Inc. ( TSXV:IBO ) (“ UI ” or the “ Company ”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, advises that it is in process of finalizing an offering (the “ Offering ”) of convertible debt securities.  The Offering will consist of “Secured Guarantee Convertible Notes” (the “ Notes ”) which will bear interest at [...]

Vancouver, BC / December 1, 2022 / Universal Ibogaine Inc. (the “Company”) (TSXV: IBO) is pleased to announce that it has closed its non-brokered private placement of convertible notes (the “Notes”) previously announced on October 3, 2022. (the “Debt Offering”) The Company has issued Notes in the aggregate principal amount of $626,500 CAD. The Notes shall mature 3 years from [...]